Prior to CFTR modulators era, children with CF spent approximately 75 min for treatment tasks according to Ziaian et al. [20] Several studies in adolescents and adults have shown that ETI reduces the daily treatment burden [21], allowing to de‐escalate supportive therapy without worsening in lung function in ≥ 6 year old patients [22] and ≥ 12‐year‐old patients [23]. Here, CFTR is linked to cystic fibrosis.